Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin AmyloidosisDavid Adams, Ole B. Suhr, Mitsuharu Ueda et al.|New England Journal of Medicine|2018Cited by 2.9k
Vutrisiran in Patients with Transthyretin Amyloidosis with CardiomyopathyMarianna Fontana, Mathew S. Maurer, John L. Berk et al.|New England Journal of Medicine|2024Cited by 356